Clinical Publications	Scientific Publications
December 2022
Project Confirm: Accelerated drug approvals for chronic myeloid leukemia Sweet KL et al. Clin Cancer Res, December 2022 (epub ahead of print)
Management of TKI-resistant chronic phase CML - Review Hughes TP and Shanmunagathan N. Hematology Am Soc Hematol Educ Program, December 2022	Genetic landscape of chronic myeloid leukemia - Review Ochi Y. Int J Hematol, December 2022 (epub ahead of print)
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic-phase: the ASC4FIRST phase III trial Cortes JE et al. Future Oncol, December 2022 (epub ahead of print) - open access publication	Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition Bütow M et al. Haematologica, December 2022 (epub ahead of print) – open access publication
Treatment of CML in pregnancy Robertson HF and Apperley JF. Hematology Am Soc Hematol Educ Program, December 2022	Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation Karg E et al. Front Oncol, December 2022 – open access publication
Measurable residual disease in leukemia - Review Branford S and Apperley JF. Haematologica, December 2022 – open access publication	Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukemia (CML) by disrupting glycerophospholipid metabolism Gonzalez MA et al. Clin Transl Med, December 2022 – open access publication
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM1 trial Dulucq S et al. Haematologica, December 2022 – open access publication	JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? Tarantini F et al. Hematology, December 2022
Chronic myeloid leukemia: the cutting-edge evidence and things we should know Iriyama N et al. Int J Hematol, December 2022 (epub ahead of print)	Wee 1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-yH2AX-MDC1 Zeng F et al. Cell Commun Signal, December 2022 – open access publication
De novo lymphoid blast phase chronic myeloid leukemia: report and contemporary discussion Hameed M et al. Hematology, December 2022 – open access publication	Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicated chronic myeloid leukemia cells Dudka W et al. BMC Cancer, December 2022 – open access publication
Current management of chronic myeloid leukemia myeloid blast crisis - Review Yohanan B and George B. Clin Med Insights Oncol, December 2022 (epub ahead of print)	Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells Zhang J et al. Hematology, December 2022
A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia - Review Ahmed K et al. Front Med (Lausanne), December 2022 – open access publication	Aberrant DNA methylation status and mRNA expression level of SMG1 gene in chronic myeloid leukemia: A case-control study Hojjatipour T et al. Cell J, December 2022
A review of the therapeutic role of the new third-generation TKI Olverembatinib in chronic myeloid leukemia - Review Qian H et al. Front Oncol, December 2022 - open access publication	Correlation of the transcription factors IRF4 and BACH2 with the abnormal NFATC1 expression in T cells from chronic myeloid leukemia patients Zhang Y et al. Hematology, December 2022
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study Ono T et al. Int J Hematol, December 2022 – open access publication	FUBP3 regulates chronic myeloid leukemia progression through PRC2 complex regulated PAK1-ERK signalling Sharma M et al. J Cell Mol Med, December 2022 (epub ahead of print) – open access publication
Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia Ureshino H et al. Hematology, December 2022 – open access publication	Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor Liu H et al. Eur J Med Chem, December 2022
Transplantation in CML in the TKI era: who, when, and how? Niederwieser C and Kröger N. Hematology Am Soc Hematol Edu Program, December 2022	miR-495-3p sensitizes BCR-ABL1 expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance1 gene in T315I mutated cells Rittavee Y et al. Exp Hematol, December 2022 (epub ahead of print)
	Dvl proteins regulate SMAD1, AHR, mTOR, BRD7 protein expression while differentially regulating canonical and non-canonical Wnt signaling pathways in CML cell lines Caliskan C et al. Gene, December 2022 (epub ahead of print)
November 2022
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia Flynn KE et al. Haematologica, November 2022 – open access publication	BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia Parry N et al. Cell Death Discov, November 2022 – open access publication
Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands Ector GICG et al. Leuk Lymphoma, November 2022 (epub ahead of print)	Integrating single-cell transcriptome and network analysis to characterize the therapeutic response of chronic myeloid leukemia Ma J et al. Int J Mol Sci, November 2022 – open access publication
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis Jabbour E et al. Am J Hematol, November 2022	Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia Knight A et al. Cancer Immunol Immunother, November 2022 (epub ahead of print) – open access publication
Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotonib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis - Review Li S et al. Front Cardiovas Med, November 2022 - open access publication	Intracellular angiopoietin-1 promotes TKI-resistance via activation of JAK/STAT5 pathway in chronic myeloid leukemia Ma D et al. Oncogene, November 2022 (epub ahead of print)
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with chronic myeloid leukemia Ono T et al. Cancer Sci, November 2022 (epub ahead of print) – open access publication	Low c-Kit expression identifies primitive therapy-resistant CML stem cells Shah M et al. JCI Insight, November 2022 (epub ahead of print) – open access publication
Olverembatinib in chronic myeloid leukemia Öziskender R et al. Drugs Today (Barc), November 2022	Hematopoietic and chronic myeloid leukemia stem cells: Multi-stability versus lineage restriction - Review Brown G. Int J Mol Sci, November 2022 – open access publication
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation Xu Z et al. Leuk Lymphoma, November 2022	SLIT2 promoter hypermethylation predicts disease progression in chronic myeloid leukemia Wu DL eta l. Eur J Med Res, November 2022 – open access publication
Extramedullary T-lymphoblastic blast crisis in chronic myeloid leukemia: A very rare case associated with comutation of ABL1 T315I and H396R Zhang Y et al. Int J Lab Hematol, November 2022 (epub ahead of print)	Reciprocal interactions among CobII1, PACSIN2, and SH3BP1 regulate drug resistance in CML Park K et al. Cancer Med, November 2022 – open access publication
A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast crisis and was successfully treated with asciminib Tomassetti S et al. Clin Case Rep, November 2022 – open access publication	Low c-Kit expression identifies primitive therapy-resistant CML stem cells Shah M et al. JCI Insight, November 2022 (epub ahead of print) – open access publication
October 2022
Allogeneic hematopoietic cell transplantation in patients with CML chronic phase in the era of third generation tyrosine kinase inhibitors: a retrospective study by the Chronic Malignancies Working Party in the EBMT Chalandon Y et al. Am J Hematol, Oct 2022 (epub ahead of print) – open access publication	Secondary fusion proteins as a mechanism of BCR::ABL1 kinase independent resistance in chronic myeloid leukemia Barnes EJ et al. Br J Haematol, Oct 2022 (epub ahead of print)
Dasatinib plus Peg-interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukemia: Results of a multicenter phase 2 study (DASA-Peg IFN Study) Roy L et al. Br J Haematol, Oct 2022 (epub ahead of print)	Prognostic impact of ASXL1 mutations in chronic phase CML Bidikian A et al. Blood Cancer J, Oct 2022 – open access publication
B-lymphoid blast phase chronic myeloid leukemia: Current Therapeutics Yohannan B and George B. Int J Mol Sci, Oct 2022 – open access publication	Non-coding RNAs are implicit in chronic myeloid leukemia therapy-resistance - Review Rudich A et al. Int J Mol Sci, Oct 2022 – open access publication
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency Hochmann MJ et al. Int J Hematol, Oct 2022 (epub ahead of print)	ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescene by regulating SIRT1/p53/p21 pathway Liu W et al. Sci Rep, Oct 2022 – open access publication
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency Hochmann MJ et al. Int J Hematol, Oct 2022 (epub ahead of print)	Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia Su YL et al. Cancer Sci, Oct 2022 – open access publication
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia - Review Senapati J et al. Leukemia, Oct 2022 (epub ahead of print)	IRF4 Gene expression on the trail of molecular response: looking at chronic myeloid leukemia from another perspective Tarantini F et al. Acta Haematol, Oct 2022 (epub ahead of print)
Real-world therapeutic response and tyrosine kinase discontinuation in chronic-phase chronic myeloid leukemia: data from the French Observatory Saugues S et al. Ann Hematol, Oct 2022	Histone chaperone ASF1A accelerates chronic myeloid leukemia blast crisis by activating Notch signaling Yiu X et al. Cell Death Dis, Oct 2022 – open access publication
Bosutinib-induced late-onset severe liver injury preceded by eopsinophilia Watanabe N et al. Ann Hematol, Oct 2022
BCR::ABL1 levels at first month after tyrosine kinase inhibitor discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC” Di Giusto S et al. Cancer Med, Oct 2022 (epub ahead of print) – open access publication
Volumetric dried blood micro-sampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia Krützmann ME et a. J Pharm Biomed Anal, Oct 2022 (epub ahead of print)	Co-existence of chronic lymphocytic leukemia and chronic myeloid leukemia and underlying pathogenetic mechanisms Badal S et al. Eur J Haematol, Oct 2022 (epub ahead of print)
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care Assanto GM et al. Expert Rev Hematol, Oct 2022 (epub ahead of print)	EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells Vinothkumar K et al. Int J Hematol, Oct 2022 (epub ahead of print)
CML resistant to 2nd generation TKI’s: Mechanisms, next steps, and new directions Scalzulli E et al. Curr Hematol Malig Rep, October 2022 (epub ahead of print)	Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. Focus on immunological pathways Janowski M et al. Onco Targets Ther, Oct 2022 – open access publication
	Association between germline single-nucleotide variants in ADME genes and major molecular response to imatinib in CML patients Estrada N et al. J Clin Med, Oct 2022
September 2022
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia Schönfeld L et al. Leukemia, September 2022 – open access publication	IFN- α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia Huuhtanen J et al. J Clin Invest, September 2022 – open access publication
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring Jabbour E and Kantarjian H. Am J Hematol, September 2022	Targeting the PTP1B-BCR-ABL1 interaction for the degradation of T315I mutant BCR-ABL1 in chronic myeloid leukemia Elgehama A et al. Cancer Sci, September 2022 (epub ahead of print) – open access publication
CD34-selected allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in the tyrosine kinase era Vaughn JL et al. Bone Marrow Transplant, September 2022 (epub ahead of print)	Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia Soverini S et al. Leukemia, September 2022
Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population Kockerols CCB et al. Haematologica, September 2022 (epub ahead of print) – open access publication	Ex vivo expansion of phenotypic and transcriptome CML stem cells Patel SB et al. Exp Hematol, September 2022 (epub ahead of print) – open access publication
Deep molecular response in patients with chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TMT614 combined with a tyrosine kinase inhibitor Takahashi N et al. Cancer Med, September 2022 (epub ahead of print) – open access publication	Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance Bührer ED et al. Leukemia, September 2022 (epub ahead of print) – open access publication
Management of chronic myeloid leukemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicine Agency (AIFA) Breccia M et al. Br J Haematol, September 2022 – open access publication	circCRKL, a circ RNA-derived from CRKL, regulates BCR-ABL via sponging miR-877-p5 to promote chronic myeloid leukemia cell proliferation Wang J et al. J Transl Med, September 2022 – open access publication
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities – Review Narli Özdemir Z et al. Int J Hematol, September 2022 (epub ahead of print)	KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukemia though activating Wnt/ß-catenin pathway Huang Y et al. Clin Exp Pharmacol Physiol, September 2022 (epub ahead of print) – open access publication
Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia – Review Umezawa Y and Sasaki K. Int J Hematol, September 2022 (epub ahead of print)
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitors? Canon A et al. Leuk Lymphoma, September 2022 (epub ahead of print)
Asciminib vs bosutinib in CML patients pretreated with ≥ 2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL Study Yuda J et al. Cancer Med, September 2022 (epub ahead of print) – open access publication
A unique three-way variant Philadelphia chromosome t(6;9;22) (p21.3;q34;q11.2) in a newly diagnosed patient with chronic myeloid leukemia responded to Flumatinib Chen L et al. Onco Targets Ther, September 2022 – open access publication
August 2022
Defining higher-risk chronic myeloid leukemia: risk scores, genomic landscape, and prognostication – Review Shahrin NH et al. Curr Hematol Malig Rep, August 2022 (epub ahead of print) - open access publication	Reengineering ponatinib to minimize cardiovascular toxicity Hnatiuk AP et al. Cancer Res, August 2022
Onset of blast crisis in chronic myeloid leukemia in treatment-free remission Dulucq S et al. Haematologica, August 2022 (epub ahead of print) – open access publication	Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in TKI-resistant CML cells Kaehler M et al. Oncol Rep, August 2022 – open access publication
Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia Johnson-Ansah H et al. Pharmaceutics, August 2022 – open access publication	Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-alderosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia Tsuda M et al. Int J Hematol, August 2022 (epub ahead of print)
Asciminib as a third line option in chronic myeloid leukemia - Review Laganà A et al. Int J Hematol, August 2022 (epub ahead of print)	Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors Hong Y et al. Int Immunopharmacol, August 2022
The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era Kockerols CCB et al. Haematologica, August 2022 – open access publication	Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR:ABL1-independent resistance to tyrosine kinase inhibitors Mancini M et al. Front Oncol, August 2022 – open access publication
Caution in using second generation tyrosine kinase inhibitor, especially for first-line therapy of chronic myeloid leukemia Gambarcorti-Passerini C et al. Am J Hematol, August 2022 – open access publication	Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial Yen R et al. Leukemia, August 2022 (epub ahead of print)
Real-life analysis and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia Luna A et al. Ann Hematol, August 2022 (epub ahead of print) – open access publication	The mRNA expression of PTEN, LEF1, JAK3, LC3, and p62/SQSTM1 genes in patients with chronic myeloid leukemia Lak ER et a. Cardiovas Hematol Agents Med Chem, August 2022
Olverembatinib (HQP135I), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated CML: results of an open-label, multicenter phase 1/2 trial Jiang Q et al. J Haematol Oncol, August 2022 – open access publication	Activin A downregulates the CD69-MT2A axis via p38 MAPK to induce erythroid differentiation that sensitized BCR-ABL-positive cells to imatinib Chen CW et al. Exp Cell Res, August 2022
TKI dosing for chronic phase CML: the case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day) Tefferi A et al. Am J Hematol, August 2022 (epub ahead of print)
Identification of key microRNA as predictive biomarkers of nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial Yen R et al. Leukemia, August 2022 (epub ahead of print)
Impact of emerging ACA on survival in chronic myeloid leukemia (CML) Hehlmann R et al. Leukemia, August 2022 (epub ahead of print) – open access publication
July 2022
Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors Aslan NA et al. J Oncol Pharma Pract, July 2022 – open access publication	Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA Sánchez R et al. Sci Rep, July 2022 – open access publication
Mechanisms of resistance and implications for treatment strategies in CML - Review Poudel C et al. Cancers(Basel), July 2022 – open access publication	Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia Su YJ et al. Cancer Sci, July 2022 (epub ahead of print) – open access publication
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase - Review García-Gutiérrez V et al. J Hematol Oncol, July 2022 – open access publication	RHOA regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia Zhang H et al. Haematologica, July 2022 (epub ahead of print) – open access publication
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors Haddad FG et al. Am J Hematol, July 2022	Vandetanib drives growth arrest and promotes sensitivity to Imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4 Ma W et al. Mol Oncol, July 2022 – open access publication
Exposure-efficacy analysis of Asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic-phase Combes FP et al. Clin Pharmacol Ther, July 2022 (epub ahead of print)	BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia Peter B et al. Am J Hematol, July 2022 (epub ahead of print)- open access publication
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor chronic myeloid leukemia patients Lipton NJ and Lipton JH. Leuk Lymphoma, July 2022	Chronic myeloid leukemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype Harrington P et al. Br J Haematol, July 2022 (epub ahead of print) – open access publication
Induction-maintenance for the chronic-phase of chronic myeloid leukemia (IMPACT-I): a prospective, single-arm, phase 2 study Cheung YM et al. Lancet Oncol, July 2022	Allosteric enhancement of the BCR-ABL1 kinase inhibition activity of Nilotinib by co-binding of Asciminib Oruganti B et al. J Biol Chem, July 2022 (epub ahead of print) – open access publication
Co-variates associated with outcomes of tyrosine kinase inhibitor therapy in persons with chronic myeloid leukemia initially presenting in accelerated phase Yang S et al. Leukemia, July 2022	Complex karyotype with double Philadelphia chromosome and T315l mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient Davulcu EA et al. Cancer Genet, July 2022 (epub ahead of print)
Migrating to long-read sequencing for clinical routine BCR-ABL1 TKI resistance mutation screening Schaal W et al. Cancer Inform, July 2022 – open access publication	Simultaneous quantification of Dasatinib, Nilotinib, Bosutinib, and Ponatinib using high-performance liquid chromatography-Photodiode array detection Yokoyama Y et al. J Clin Lab Anal, July 2022 (epub ahead of print) – open access publication
Treatment of blast phase chronic myeloid leukemia: A rare and challenging entity – Review Copland M. Br J Haematol, July 2022 (epub ahead of print) – open access publication	Inability to phosphorylate Y88 of P27Kip1 enforces reduced P27 protein levels and accelerated leukemia progression Jäkel H et al. Leukemia, July 2022 – open access publication
Chronic phase CML with sole P190 (e1a2) BCR:ABL1: long-term outcome among ten consecutive cases Abdelmagid MG et al. Blood Cancer J – open access publication
June 2022
Asciminib for chronic myeloid leukemia: Next questions - Review Shanmuganathan N and Hughes TP. Br J Haematol, June 2022 (epub ahead of print)	CRISPR/Cas9-directied gene trap constitutes a selection system for corrected BCR/ABL leukemic cells in CML Vuelta E et al. Int J Mol Sci, June 2022 – open access publication
Initial rate of BCR::ABL1 decline for response prediction in chronic myeloid leukemia Branford S. Turk J Haematol, June 2022 (epub ahead of print) – open access publication	Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML Liu C et al. Cell Metabol, June 2022
French Chronic Myeloid Leukemia Intergroup 2022 recommendations for managing the risk of cardiovascular events on ponatinib in chronic myeloid leukemia (In French) Réa D et al. Bull Cancer, June 2022 (epub ahead of print)	The dawn of allosteric BCR-ABL1 drugs: from a phenotypic screening hit to an approved drug Teng M et al. J Med Chem, June 2022 (epub ahead of print)
Chronic myeloid leukemia: 2022 update on diagnosis, therapy and monitoring Jabbour E and Kantarjian H. Am J Hematol, June 2022 (epub ahead of print)	BCR-ABL1∆E7-8-9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia Tan Y et al. Hematol Oncol, June 2022 (epub ahead of print)
Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy Zhang XS et al. Leukemia, June 2022 (epub ahead of print)	Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy Salmon M et al. Leukemia, June 2022 (epub ahead of print) – open access publication
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukemia at high risk of cardio toxicity Di Lisi D et al. ESC Heart Fail, June 2022 – open access publication	Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission Yu G et a. Leuk Lymphoma, June 2022 (epub ahead of print)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dentritic Neoplasms - Review Khoury JD et al. Leukemia, June 2022 (epub ahead of print) – open access publication	Successful preservation of native BCR::ABL1 in chronic myeloid leukemia primary leukocytes reveals a reduced kinase activity Boni C et al. Front Oncol, June 2022 – open access publication
Future management of chronic myeloid leukemia: From dose optimization to new agents Breccia M et al. Curr Cancer Drug Targets (epub ahead of print)	Modified dentritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation Du Z et al. Exp Hematol Oncol, June 2022 – open access publication
The outcomes of ponatinib therapy in patients with CML resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the Donation Program Sacha T et al. Clin Lymphoma Myeloma, June 2022 – open access publication	Atypical activation of signaling downstream of inactivated BCR-ABL mediates chemoresistance in chronic myeloid leukemia Narasimhan M et al. J Cell Commun Signal, June 2022 (epub ahead of print) – open access publication
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea Ahn SY et al. Blood Res, June 2022 (epub ahead of print) – open access publication	Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia Ozel B et al. Med Oncol, June 2022
Out comes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network Sanz A et al. Blood Cancer J, June 2022 – open access publication
Bosutinib-induced lung injury: a report of two cases and literature review Watanabe N et al. Int J Hematol, June 2022 – open access publication
May 2022
How I treat chronic-phase chronic myelogenous leukemia Berman E. Blood, May 2022	Bioactive lipids as chronic myeloid leukemia’s potential biomarkers for disease progression and response to tyrosine kinase inhibitors de Almeida FC et al. Front Immunol, April 2022 – open access publication
Asciminib: new therapeutic option in chronic-phase CML with treatment-failure Yeung DT et al. Blood, April 2022 (epub ahead of print)	RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia Shanmunagathan N et al. J Mol Diagn, May 2022 (epub ahead of print)
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission Lu L et al. Br J Haematol, May 2022 (epub ahead of print) – open access publication	Novel tyrosine kinase inhibitors to target chronic myeloid leukemia Ciaffaglione V et al. Molecules, May 2022 – open access publication
Chronic myeloid leukemia: a type of MPN Samad MA et al. Blood Res, May 2022 (epub ahead of print) – open access publication	Chromosomal instability in chronic myeloid leukemia: Mechanistic insights and effects Senapati J and Sasaki K. Cancers(Basel), May 2022 – open access publication
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia – What to look for when treatment-free remission is not an option Lipton JH et al. Blood Rev, May 2022 (epub ahead of print) – open access publication	LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients Shehata AMF et al. Leuk Res, May 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial Brümmendorf TH et al. Leukemia, May 2022 (epub ahead of print) – open access publication	Peripheral blood CD26 positive leukemia stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia Ebjan HF et al. Leuk Res Rep, May 2022 – open access publication
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia Flynn KE et al. Haematologica, May 2022 (epub ahead of print) – open access publication
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study White HE et al. Leukemia, May 2022 (epub ahead of print) – open access publication
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia Yang J et al. Expert Rev Hematol, May 2022 (epub ahead of print)
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM-2 trial Dulucq S et al. Haematologica, May 2022 (epub ahead of print) – open access publication
Lower tumour burden is associated with better cognitive function in patients with chronic-phase chronic myeloid leukemia Li Z et al. Leuk Lymphoma, May 2022 (epub ahead of print)
Long-term outcomes of patients with chronic myeloid leukemia who commenced treatment with imatinib: a 20-year single-centre experience Szczepanek E et al. Leuk Lymphoma, May 2022 (epub ahead of print)
April 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study Gugliotta G et al. Haematologica, April 2022 (epub ahead of print) – open access publication	Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide Zheng X et al. Oncol Lett, April 2022 – open access publication
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia: eligibility criteria and predictors of success Inzol E et al. Am J Hematol, April 2022 (epub ahead of print) – open access publication	Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation Adnan Awad S et al. Blood Cancer J, April 2022 – open access publication
Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia Haddad F et al. Leuk Lymphoma, April 2022 (epub ahead of print)	A berrant hyrdroxymethylation in promoter CpG regions of genes related to the cell cycle apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival Guru SA et al. BMC Cancer, April 2022 – open access publication
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation Shimazu Y et al. Hematol Oncol, April 2022 (epub ahead of print)	Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy Li Y et al. Cell Death Discov, April 2022 – open access publication
Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukemia Shivarov V and Grigorova D. Br J Haematol, April 2022 (epub ahead of print) – open access publication
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic leukemia in the United Kingdom and The Netherlands Claudiani S et al. Eur J Haematol, April 2022 (epub ahead of print)
Quantification of atypical BCR-ABL1 fusion transcripts in patients with chronic myeloid leukemia: Which approach for harmonization? Bhreathnach Ú and Langabeer SE. Int J Lab, April 2022 (epub ahead of print) – open access publication
Aleukemic extramedullary blast crisis as an initial presentation of chronic myeloid leukemia with E1A3 BCR-ABL1 fusion transcript Miyashita N et al. Int Med, April 2022 (epub ahead of print) – open access publication
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors García-Gutiérrez V and Hernandez-Boluda JC. Expert Rev Hematol, May 2022 (epub ahead of print)
March 2022
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis Takahashi N et al. Int J Hematol, March 2022 (epub ahead of print) – open access publication	Another Philadelphia story Radich J. Haematologica, March 2022 – open access publication
Michele Baccarani, August 16, 1942 to December 20, 2021: a gifted life in hematology Saglio G et al. Bone Marrow Transplant, March 2022 (epub ahead of print) – open access publication	The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients Park H et al. Leuk Res, March 2022
Treatment-free remission in chronic myeloid leukemia patients treated with low-dose TKIs: A feasible option also in real-life: A Campus CML study Iurlo A et al. Front Oncol, March 2022 – open access publication	The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia Kumar R et al. Blood Adv, March 2022 (epub ahead of print) – open access publication
Prevalence of anemia among chronic myeloid leukemia patients treated with imatinib: A evidence based meta-analysis Singh AK et al. Curr Rev Clin Exp Pharmacol, March 2022 (epub ahead of print)	Targeting BCR-ABL in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia Roskoski R. Pharmacol Res, March 2022 (epub ahead of print)
Molecular monitoring of BCR-ABL fusion transcripts in patients with chronic myeloid leukemia during treatment using the endpoint fluorescence method Amin H and Ahmed S. Lab Med, March 2022	A kinase inhibitor which specifically targets the ABL myristate pocket (STAM), but unlike asciminib crosses the blood-brain barrier Manley PW et al. Bioorg Med Chem Lett, March 2022
The clinical significance of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive chronic myeloid leukemia who underwent allogeneic hematopoietic cell transplantation Tachibana T et al. Transplant Cell Ther, March 2022 (epub ahead of print)	FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via non-canonical κB-kappa B signaling activation Yang T et al. J Exp Clin Cancer Res, March 2022 – open access publication
Outcomes of pregnancies with chronic myeloid leukemia in the tyrosine kinase inhibitor era and literature review Castillo DL et al. Hematol Rep, March 2022 – open access publication	Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapyExpression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukemia patients during the first year of imatinib therapy Toloza MJ et al. Gene, March 2022
Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentrations in patients with chronic myeloid leukemia receiving first-line nilotinib therapy Fukuda N et al. Cancer Chemother and Pharmacol, March 2022 (epub ahead of print) – open access publication	MiR-199a-3p overexpression suppressed cell proliferation and sensitized chronic myeloid leukemia cells to imatinib by inhibiting mTor signalling Liu X et al. Acta Hematol, March 2022 (epub ahead of print)
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukemia Baccarani M et al. Leukemia, March 2022 (epub ahead of print) – open access publication
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukemia model Lindström HJG and Friedmann R. Sci Rep, March 2022 – open access publication
February 2022
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation Shatty D et al. Asia Pac J Clin Oncol, February 2022 – open access publication	TRIB2 regulates the expression of miR-33a-5p through the ERK/c-Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells Sun H et al. Int J Oncol, March 2022 (epub ahead of print) – open access publication
Impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A Pairwise and Bayesian Network Meta-Analysis Chen K et al. Front Oncol, February 2022 – open access publication	A systematic review of candidate miRNAs, its targeted genes and pathways in CML – An integrated bioinformatical analysis Elias MH et al. Front Oncol, March 2022 – open access publication
Extramedullary early T-cell lymphoblastic crisis in a young pregnant chronic myeloid leukemia patient: Diagnosis with fine needle aspiration cytology and flow cytometry Murugan R et al. Diagn Cytopathol, Feb 2022 (epub ahead of print)	Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia cells Ianniciello A and Helgasson GV. Autophagy, March 2022 (epub ahead of print)
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive phase in Taiwan Hwang WL et al. Int J Hematol, February 2022 (epub ahead of print)	Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia Lee KL et al. Leukemia, March 2022 – open access publication
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia Shelton DN et al. PLoS One, March 2022 – open access publication	Commentary on Dominy et al.: Assessment of qualitative PCR for BCR-ABL1 transcripts in CML: Are improved outcomes in patients with e14a2 transcripts an artefact of technology? Branford S. Br J Haematol, February 2022 (epub ahead of print) – open access publication
Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania Robin JB et al. Ann Hematol, March 2022 (epub ahead of print)	Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia Sharma P et al. Int J lab Hematol, February 2022 (epub ahead of print)
Management of chronic myeloid leukemia and pregnancy: A Bibliometric Analysis (2000-2020) Wang Y et al. Front Oncol, March 2022 – open access publication	Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study) Sicuranza A et al. Front Oncol, February 2022 – open access publication
Transcript and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review Kumar V et al. Mol Cell Biochem, February 2022 (epub ahead of print)	Genomic mechanisms influencing outcome in chronic myeloid leukemia Fernandes A et al. Cancers(Basel), January 2022 – open access publication
Olverembatinib: First Approval Dhillon S et al. Drugs, February 2022 (epub ahead of print)	Discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a review of the biological factors associated with treatment-free remission Stuckey R et al. Curr Oncol Rep, February 2022 (epub ahead of print)
A predictive scoring system for therapy failure in persons with chronic myeloid leukemia receiving initial imatinib therapy Zhang XS et al. Leukemia, February 2022 (epub ahead of print)	Validation and refinement of RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia Lee KL et al. Leukemia, February 2022 (epub ahead of print) – open access publication
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia Pokorny R et al. J Oncol Pharm Pract, February 2022 (epub ahead of print) – open access publication	Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia Kamachi K et al. Cancer Lett, February 2022 – open access publication
	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia Closa L et al. HLA, February 2022
	Waking up CML leukemia stem cells for the kill Lv K and Tong W. Blood, February 2022 – open access publication
	Identification of peripheral blood CD26+ leukemia stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia Sharma P et al. Int J lab Hematol, February 2022 (epub ahead of print)
	Pro-inflammatory and pro-oxidative changes during nilotinib treatment in CML patients: Results of a prospective multicenter frontline TKI’s study (KIARO study) Sicuranza A et al. Front Oncol, February 2022 – open access publication
	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia Closa L et al. HLA, February 2022
January 2022
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukemia Gallipoli P et al. Br J Haematol, January 2022 (epub ahead of print) – open access publication	The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemia cell differentiation Shahzad Ali M et al. J Clin Med, January 2022 – open access publication
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee Januzzi JL et al. J Hematol Oncol, January 2022 – open access publication	BCR-ABL1 tyrosine kinase complex signalling transduction: challenges to overcome resistance in chronic myeloid leukemia Amarante-Mendes GP et al. Pharmaceutics, January 2022 – open access publication
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002 – 2017 in a complete coverage and nationwide agnostic register study Dahlén T et al. Am J Hematol, January 2022 (epub ahead of print) – open access publication	Imatinib can act as an allosteric activator of ABL kinase Xie T et al. J Mol Biol, January 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1 Réa D and Hughes TP. Crit Rev Oncol Hematol, January 2022 (epub ahead of print) – open access publication	Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors Tanaka Y et al. Nat Commun, January 2022 – open access publication
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology? Dominy KM et al. Br J Haematol, January 2022 (epub ahead of print)	MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: A meta-analysis Louati N et al. J Oncol Pharma Pract, January 2022
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: Who can benefit the most? Efficace F and Baccarani M. J Natl. Cancer Inst, January 2022 – open access publication	Comparative gene expression analysis reveals similarities and differences of chronic myeloid leukemia phases Schwarz A et al. Cancers(Basel), January 2022 – open access publication
The progression of chronic myeloid leukemia to myeloid sarcoma: A systematic review Arzoun H et al. Cureus, January 2022 – open access publication	P-Loop mutations-negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients Kaleem B et al. Int J Lab Hematol, January 2022 (epub ahead of print)
Asciminib: First Approval Deeks ED et al. Drugs, January 2022 (epub ahead of print)	The prognosis biomarkers based on m6A-related IncRNAs for myeloid leukemia patients Yang LR et al. Cancer Cell Int, January 2022 – open access publication
Late responses in patients with chronic myeloid leukemia initially refractory to tyrosine kinase inhibitors Shaya J et al. Clin Lymphoma Myeloma Leuk, January 2022 – open access publication	Pterostilbene downregulated BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells Kawakami S et al. Sci Rep, January 2022 – open access publication
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia Kee KM et al. Leuk Res, January 2022	Novel mechanism by a Bis-Pyridinium fullerene derivate to induce apoptosis by enhancing the MEK-ERK pathway in a reactive oxygen species-independent manner in BCR-ABL-positive chronic myeloid leukemia-derived K562 cells Sumi K et al. Int J Mol, January 2022 – open access publication

Climb the Annapurna Base Camp and Raise Vital Funds to Help Find a Cure for CML.

By supporting the iCMLf Climb for a Cure Annapurna 2023, you’ll provide the iCMLf with funds to get closer to a cure. Show your support through climbing! You can be part of the team and we can raise funds together and spread the word about climbing for a cure and making Annapurna 2023 our most successful climb yet.

‘Over the last 10 years I’ve seen first hand the powerful impact that the global leaders in CML all working together can have to improve the lives of CML patients all over the world. There are so many people alive now as a direct result of our efforts. I can’t wait to see this power harnessed as we work to develop a cure for CML.'  (Nicola Evans, Chief Executive of the iCMLf)

Every dollar raised through Climb For a Cure Annapurna 2023 will allow us to further drive the global effort working towards a cure for CML.

Various members of the iCMLf team will be climbing, will you help us in our quest to find a cure?

I want to donate to the Climb For a Cure Annapurna 2023
I want to register for the Climb For a Cure Annapurna 2023

The 2022 John Goldman charity Fun Run raised over $1,700 so far. What a great achievement!

A special thank you to all for participating in our charity run T-shirt and to everyone for your generous contributions to support the work of the iCMLf. These funds will make a huge difference to help the iCMLf to support young scientists and physicians in low- and middle-income countries.

This year, everyone can be involved in the John Goldman Charity Fun Run.

This year you can do your own 5 km run and join the CML community virtually for the John Goldman Fun Run. Challenge yourself and join us!
The virtual run will be open until November 4^th.

Register to participate
Make your donation
Invite friends, family and colleagues to join you
Do your 5 km run challenge and have fun
Send us your photo to info@cml-foundation.org!

Congratulations and thanks to everyone for their contributions!

CML publications 2021

Clinical Publications	Scientific Publications
December 2021
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients Breccia M et al. Expert Rev Hematol, December 2021 (epub ahead of print)	Shedding light on targeting chronic myeloid leukemia stem cells Houshmand M et al. J Clin Med, December 2021 – open access publication
Low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial Murai K et al. Lancet Haematol, December 2021	Antimetabolic cooperativity with the clinically approved L-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells Trinh A et al. Mol Metab, December 2021 – open access publication
Low-dose dasatinib: when less can be more Amrein PC. Lancet Haematol, December 2021	Description of PTPRG genetic variants identified in a cohort of chronic myeloid leukemia patients and their ability to influence response to tyrosine kinase inhibitors Ismail MA et al. Gene, December 2021 (epub ahead of print) – open access publication
Blast and accelerated phase CML: room for improvement How J et al. Hematology Am Soc Educ Program, December 2021 – open access publication	Quantitative proteomic analysis of plasma exosomes to identify the candidate biomarker of imatinib resistance in chronic myeloid leukemia patients Li MY et al. Front Oncol, December 2021 – open access publication
Matchpoint: the game is not over for blast-phase chronic myeloid leukemia Rousselot P. Lancet Hematol, December 2021 (epub ahead of print)	Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML Fabian-Morales E et al. Int J Cancer, December 2021 (epub ahead of print) – open access publication
Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation – First case series from a single institution Young PE et al. Leuk Res, December 2021	Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study Zhang H et al. Hematology, December 2021 – open access publication
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission? Hochhaus A and Ernst T. Hematology Am Soc Hematol Educ Program, December 2021 - open access publication	Neutrophil extracellular traps are increased in chronic myeloid leukemia and are differently affected by tyrosine kinase inhibitors Telerman A et al. Cancers(Basel), December 2021 – open access publication
Lifelong TKI therapy: how to manage cardiovascular and other risks Mauro MJ. Hematology Am Soc Hematol Educ Program, December 2021 – open access publication	A bis-pyridinium fullerene derivative induces the generation of ROS in BCR-ABL-positive leukemia cells Sumi K et al. Eur J Pharmacol, December 2021 (epub ahead of print)
Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-crisis chronic myeloid leukemia (MATCHPOINT): a single-arm, multicentre phase 1/2 trial Copland M et al. Lancet Haematology, December 2021 (epub ahead of print)	Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation Ding L et al. Eur J Pharmacol, December 2021
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias Kota V et al. Leuk Res, December 2021	SOCS-2 gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatment Egeli DB et al. Leuk Lymphoma, December 2021 (epub ahead of print)
Chronic myeloid leukemia stem cells targeting therapeutic implications Mojtahedi H et al. Stem Cell Res Ther, December 2021 – open access publication	The effect of Gö6976 on chronic myeloid leukemia in vitro and in vivo Cao ZR et al. Hematology, December 2021
BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses Fenu E et al. Int J Lab Hematol, December 2021	Potential approaches versus approved or developing chronic myeloid leukemia therapy Andretta E et al. Front Oncol, December 2021 – open access publication
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second-generation tyrosine kinase inhibitor to an alternative TKI Ma CE et al. Leuk Res, December 2021
Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series Bayrak AG et al. Leuk Res, December 2021
Second-generation tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients with stable deep molecular response: A systematic review and meta-analysis Di Q et al. Comput Math Methods Med, December 2021 – open access publication
November 2021
Droplet digital PCR for BCR-ABL1 monitoring in diagnostic routine: Ready to start? Bochiccio MT et al. Cancers (Basel), Oct 2021 – open access publication	Tnfrsf4-expressing regulatory T cells promote escape of chronic myeloid leukemia stem cells Hinterbrandner M et al. JCI Insight, November 2021 (epub ahead of print) – open access publication
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs Réa D et al. Blood, November 2021	Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR203/ABL1 and circ_0051886/miR-637/ABL1 Lu YH and Huang ZY. Mol Med, November 2021 – open access publication
The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis Shoukier M et al. Haematologica, November 2021 – open access publication	Activated naïve gammadelta T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia Chang YY et al. Blood Cancer J, November 2021 – open access publication
Asciminib for CML: same target, new arrow Schiffer CA Blood, November 2021	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common ß chain cytokine receptor endocytosis Zhao H et al. Blood, November 2021 (epub ahead of print)
Taming the gatekeeper: ponatinib dose holds the key Branford S Blood, November 2021	Age- and gender-independent association of XRCC1 polymorphism with chronic myeloid leukemia Abdalhabib EK Int J Gen Med, November 2021 – open access publication
Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia Santos FM et al. Am J Hematol, November 2021 (epub ahead of print) – open access publication	Salidroside inhibits chronic myeloid leukemia cell proliferation and induces apoptosis by regulating the miR-140-5p/wnt5a/beta-catenin axis Chen D and Luo C. Exp Ther Med, November 2021 – open access publication
Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors Jang HJ Cancers (Basel), November 2021 (epub ahead of print)	Accurate machine-learning-based classification of leukemia from blood smear images Dese K et al. Clin Lymphoma Myeloma Leuk, November 2021
Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML Niederwieser C et al. Bone Marrow Transplant, November 2021 – open access publication	How to predict relapse in leukemia using time series data: A comparative in silicio study Hoffmann H et al. PLoSOne, November 2021 – open access publication
Asciminib as a new option in the treatment of chronic myeloid leukemia Ibis B ete al. Future Oncol, November 2021 (epub ahead of print)
Monitoring and improving adherence to tyrosine kinase inhibitors in patients with chronic myeloid leukemia: A systematic review Tan BK et al. Patient Prefer Adherence, November 2021 – open access publication
Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the US Yue X et al. Leuk Lymphoma, November 2021 (epub ahead of print)
Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors Nakamae M et al. Int J Hematol, November 2021 (epub ahead of print)
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML Webster JA et al. Leuk Res, November 2021 (epub ahead of print)
A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities Nekoukar Z et al. Blood Res, November 2021 (epub ahead of print) - open access publication
October 2021
Droplet digital PCR for BCR-ABL1 monitoring in diagnostic routine: Ready to start? Bochiccio MT et al. Cancers (Basel), Oct 2021 – open access publication	Investigation on the interaction behaviour of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein Rocha KML eta l. J Mol Mode, October 2021
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT Masouridi-Levrat S et al. Bone Marrow Transplant, October 2021 (epub ahead of print) – open access publication	Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers Krishnan V et a. Haematologica, October 2021 (epub ahead of print) – open access publication
Making treatment-free remission (TFR) easier in chronic myeloid leukemia: Fact checking and practical management tools Castagnetti F et al. Target Oncol, October 2021 (epub ahead of print) - open access publication	Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients Park H et al. Leuk Res, October 2021 (epub ahead of print)
Prediction of cardiovascular events in patients with chronic myeloid leukemia using baseline risk factors and coronary artery calcium scoring Baggio D et al. Intern Med J, October 2021	Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance Song T et al. Leukemia, October 2021
Imatinib plasma levels in patients with chronic myeloid leukemia under routine clinical practice conditions Del Rosario García B et al. J Oncol Pharm Pract, October 2021	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signalling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia Aranda-Tavío H et al. Biomed Pharmacother, October 2021 (epub ahead of print)
Pharmacokinetics of asciminib when taken with imatinib or with food Hoch M et al. Clin Pharmacol Drug Dev, October 2021 (epub ahead of print)	3D tissue engineered plasma cultures support leukemic proliferation and induces drug-resistance Alhallah K et al. Leuk Lymphoma, October 2021
Treatment-free remission: the new goal in CML therapy Atallah E and Sweet K. Curr Hematol Malig Rep, October 2021 (epub ahead of print) – open access publication	Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance Wu YY et al. Cell Death Dis, October 2021 (open access publication)
The evolving landscape of frontline therapy in chronic phase chronic myeloid leukemia (CML) Wolfe HR and Rein LAM. Curr Hematol Malig Rep, October 2021 (epub ahead of print)
The cure of leukemia through the optimist’s prism Kantarjian HM et al. Cancer, October 2021 (epub ahead of print)
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Malik S et al. Expert Rev Hematol, October 2021 (epub ahead of print)
Health-related quality of life of patients with chronic myeloid leukemia as measured by patient-reported outcomes: Current state and future directions Schoenbeck KL and Flynn KE. Curr Hematol Malig Rep, October 2021 (epub ahead of print)
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: Final report of the PhilosoPhi34 Study Pungolino E et al. Eur J Hematol, October 2021 – open access publication
Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and PH+ ALL Kawano N et al. Int J Hematol, October 2021
Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Ono T. Cancers (Basel), October 2021 - open access publication
September 2021
Quality of life improvements in patients with chronic myeloid leukemia after stopping long-term therapy: who can benefit the most? Efficace F and Baccarani M. J Natl Cancer Inst, September 2021 (epub ahead of print) - open access publication	Genetic heterogeneity in chronic myeloid leukemia: How clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcomes, and risk of cardiovascular events Sant’Antonio E et al. Clin Lymphoma Myeloma Leuk, September 2021
Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors Schoenbeck KL et al. J Natl Cancer Inst, September 2021 (epub ahead of print)	Granulocyt and monocytic myeloid-derived suppressor cells are functionally and prognostically different in patients with chronic myeloid leukemia Ahn A et al. Ann Lab Med, September 2021 – open access publication
Chronic myeloid leukemia: Modern therapies, current challenges and future directions Osman AEG and Deininger MW. Blood Rev, September 2021	Association of creatine elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study Bankar A and Lipton LH. Leuk Lymphoma, September 2021 (epub ahead of print)
Long-term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic-phase treated outside clinical trials: a real-life cohort observational study Stagno F et al. Acta Oncol, September 2021 (epub ahead of print)	Intracellular delivery of anti-BCR-ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells Jiang G et al. J Hematol Oncol, September 2021 – open access publication
Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: is there a real benefit? Canet J et al. Cancer Med, September 2021 (epub ahead of print) – open access publication	BCR-ABL1 transcript doubling time as a predictor for tre atment free remission after imatinib discontinuation in chronic myeloid leukemia Kim DDH et al. Br J Hematol, September 2021 (epub ahead of print)
Current evidence of the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs Erçaliskan A et al. Blood Adv, September 2021 - open access publication	Spred1 deficit promotes treatment resistance and transformation of chronic phase CML Qiao J et al. Leukemia, September 2021 (epub ahead of print)
How I treat chronic phase chronic myelogenous leukemia Berman E et al. Blood, September 2021 (epub ahead of print)	Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients Harada I et al. Sci Rep, September 2021 – open access publication
Chronic myeloid leukemia with pure erythroid leukemic blast crisis Jacobs JW et al. Leuk Lymphoma, September 2021 (epub ahead of print)	PKC-beta/Alox5 axis activation promotes BCR-ABL-independent TKI-resistance in chronic myeloid leukemia Ma D et al. J Cell Physiol, September 2021
Debating frontline therapy in chronic myeloid leukemia Bi X et al. Front Oncol, September 2021 – open access publication	Mitochondrial metabolism as a potential therapeutic target in myeloid leukemia de Breauchamp L et al. Leukemia, September 2021 (epub ahead of print) - open access publication
Nilotinib versus Imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroups of the randomized ENESTnd trial Nakamae H et al. Int J Hematol, September 2021 (epub ahead of print)
Response to tyrosine kinase inhibitors in real-world patients with chronic myeloid leukemia Szeto AH et al. Ann Pharmacother, September 2021 (epub ahead of print) – open access publication
Severe pleural effusion associated with nilotinib for chronic myeloid leukemia: cross-intolerance with tyrosine kinase inhibitors Satoh K et al. BMJ Case Rep, September 2021
August 2021
A phase 3, open-label, randomized study of Asciminib, a STAMP inhibitor, vs Bosutininb in CML after ≥ prior TKI’s Rea D et al. Blood, August 2021 (epub ahead of print)	ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells Yang S et al. Blood, August 2021 (epub ahead of print)
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: A randomized, open-label phase 2 clinical trial Cortes J et al. Blood, August 2021 (epub ahead of print)	Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib msylate therapy Karasu N et al. Med Oncol, August 2021
Chronic myeloid leukemia Cortes J et al. Lancet, August 2021 (epub ahead of print)	Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question. Henry A et al. Br J Haematol, August 2021 (epub ahead of print) – open access publication
Inotuzumab ozoganicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia Jain N et al. Am J Hematol, August 2021	Molecular, cytogenetic, and haematological analysis of chronic myeloid leukemia patients and discovery of two novel translocations Asif M et al. Anal Cell Pathol (Amst), August 2021 – open access publication
Pulmonary hypertension in patients with chronic myeloid leukemia Song IC et al. Medicine (Baltimore), August 2021 – open access publication	CRISPR-Cas9 technology as a tool to target gene drivers in cancer: proof of concept and new opportunities to treat chronic myeloid leukemia Vuelta E et al. CRISPR J, August 2021
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged > 65 years resistant/intolerant to previous tyrosine-kinase inhibitors Latagliata R et al. Hematol Oncol, August 2021	Genomic copy number variants in CML patients with the Philadelphia chromosome (Ph+): An update Zhang H et al. Front Genet, August 2021 – open access publication
Extramedullary blast crisis in a chronic myeloid leukemia patient after achieving a major molecular response with bosutinib Nakajima R et al. Br J Haematol, August 2021 (epub ahead of print) – open access publication	From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia Thakral B et al. Ann Diagn Pathol, August 2021
Early prediction of stable MR(4.5) by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib Nee A et al. Leuk Lymphoma, August 2021 (epub ahead of print)	KIR3DL1 allotype-dependent modulations of NK cell immunity against chronic myeloid leukemia Izumi K et al. Immunohorizons, August 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia Breccia et al. Expert Opion Investig Drugs, August 2021	MiR-150 expression in chronic myeloid leukemia: Relation to imatinib response Habib EM et al. Lab Med, August 2021 (epub ahead of print)
Is the Sokol or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Zhang XS et al. Leukemia, August 2021 (epub ahead of print) – open access publication	Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia Qing Y et al. Cell Commun Signal, August 2021 – open access publication
Tyrosine kinase inhibitor and vascular adverse events in chronic myeloid leukemia patients: a population-based, prospensity score-matched cohort study Chen MT et al. Oncologist, August 2021 (epub ahead of print) – open access publication
Long-term tolerability and efficacy after initial PegIFN- α addition to dasatinib in CML-CP – five year follow-up of the Nord CML007 study Flygt H et al. Eur J Haematol, August 2021 (epub ahead of print) – open access publication
Treatment free remission in patients with chronic myeloid leukemia: recommendations of LALNET expert panel Pavlovsky C et al. Blood Adv, August 2021 (epub ahead of print) - open access publication
Treatment-free remission in chronic myeloid leukemia: Can we identify prognostic factors? Scifullah HH and Lucas CM. Cancers (Basel), August 2021 – open access publication
July 2021
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukemia patients Rousselot P et al. Br J Haematol, July 2021	TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signalling Agarwal P et al. Cell Rep, July 2021 – open access publication
Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity Janssen L et al. Haematologica, July 2021 – open access publication	ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signalling Liu YH et al. Oncol Rep, July 2021 – open access publication
Ophthalmologic manifestations as the initial presentation of chronic myeloid leukemia: A Review Yassin MA et al. Surv Ophthalmol, July 2021 (epub ahead of print) – open access publication	Role of lysophospholipid metabolism in chronic myelogenous leukemia stem cells Naka K. Cancers(Basel), July 2021 – open access publication
Arterial hypertension assessment in a population with chronic myeloid leukemia Roa-Chamorro R et al. Sci Rep, July 2021 – open access publication	DNA methylation and intra-clonal heterogeneity: The chronic myeloid leukemia model Lebecque B et al. Cancers(Basel), July 2021 – open access publication
Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia in tyrosine kinase inhibitors Rodia R et al. J Endocrinol Invest, July 2021 (epub ahead of print) – open access publication	HNRNPH1 is a novel regulator of cellular proliferation and disease progression in chronic myeloid leukemia Liu M et al. Front Oncol, July 2021 – open access publication
Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: A Report from the Nagasaki CML Study Group Chiwata M et al. Intern Med, July 2021 – open access publication	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation and changes following interferon treatment Kong J et al. Ann Hematol, July 2021 (epub ahead of print)
Comparison of hepatotoxicity associated with new BCR-ABL tyrosine kinase inhibitors vs. imatinib among patients with chronic myeloid leukemia: A systematic review and meta-analysis Wang Z et al. JAMA Netw open, July 2021 – open access publication	Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukemia at diagnosis and early follow-up Romzova M et al. Br J Haematol, July 2021 (epub ahead of print)
Impact of BCR-ABL1 transcript type on response, treatment-free remission rate and survival in chronic myeloid leukemia patients treated with imatinib Marcé S et al. J Clin Med, July 2021 – open access publication
Quality of life among chronic myeloid leukemia patients in the second line treatment with nilotinib and influential factors Nguyen CTT et al. Quali Life Res, July 2021 (epub ahead of print)
Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy Oswald LB et al. Support Care Cancer, July 2021 (epub ahead of print)
June 2021
Impact of frontline treatment approach on outcome of myeloid blast phase CML Saxena K et al. J Hematol Oncol, June 2021 – open access publication	Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia Shindo T et al. Immunol Med, June 2021
Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy Cortes J et al. Eur J Haematol, June 2021 – open access publication	Gata2-L359V impairs primitive and definitive hematopoiesis nd blocks cell differentiation in murine chronic myelogenous leukemia models Fu YK et al. Cell Death Dis, June 2021 – open access publication
Measuring prognosis in chronic myeloid leukemia: What’s new? Breccia M et al. Expert Rev Hematol, June 2021 (epub ahead of print)	Zfp36I1 plays an ambiguous role in the regulation of cell expansion and negatively regulates Cdkn1a in chronic myeloid leukemia cells Kaehler M et al. Exp Hematol, June 2021 (epub ahead of print)
Treatment-free remission of chronic myeloid leukemia in real-world practice by the detected limit of MR4.3 Park P et al. Leuk Res, June 2021	Cytochrome P4502C19 gene polymorphisms (CYP2C192 and CYP2C193) in chronic myeloid leukemia patients: in vitro and in silico studies Joshi K et al. J Biomol Struct Dyn, June 2021 (epub ahead of print)
Appropriate starting does of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia Shin H et al. Clin Lymphoma Myeloma Leuk, June 2021	Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukemia: mass spectrometry versus next generation sequencing Shanmunagathan N and Branford S. Br J Haematol, June 2021 (epub ahead of print)
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia Breccia M et al. Expert Opin Investig Drugs, June 2021 (epub ahead of print)	Metabolic alterations mediated by STAT3 promotes drug persistence in CML Patel SB et al. Leukemia, June 2021 (epub ahead of print) - open access publication
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience Ureshino H et al. Hematol Oncol, June 2021 (epub ahead of print)	CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells Kim JH et al. Biochem Pharmacol, June 2021 (epub ahead of print)
Successful tyrosine kinase inhibitor discontinuation outside clinical trials – data from the population-based Swedish CML Registry Flygt H et al. Br J Haematol, June 2021 – open access publication	Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukemia in an International interlaboratory study Scott S et al. Br J Haematol, June 2021 (epub ahead of print) – open access publication
Pharmakokinetics of Asciminib in individuals with hepatic or renal impairment Hoch M et al. J Clin Pharmacol, June 2021 (epub ahead of print)	Positive interactions between STAP1 and BCR-ABL influences chronic myeloid leukemia cell proliferation and survival Ishiura M et al. Biochem Biophys Res Comm, June 2021
Perspectives and emotional experiences of patients with chronic myeloid leukemia during ENESTPath clinical trial and treatment-free remission: Rationale and protocol of the Italian substudy Borghi L et al. Front Oncol, May 2021 – open access publication	Targeting FEN1 suppresses the proliferation of chronic myeloid leukemia cells through regulating alternative end-joining pathways Zhu Y et al. DNA Cell Biol, June 2021 (epub ahead of print)
Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia Shoukier M et al. Curr Oncol Rep, June 2021	Brefeldin A induces apoptosis, inhibits BCR-ABL activation, and triggers BCR-ABL degradation in CML K562 cells Zhang JM et al. Anticancer Agents Med Chem, June 2021 (epub ahead of print)
Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia: final report of the PhilosoPhi34 study Pungolino E et al. Eur J Haematol, June 2021 (epub ahead of print)	Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells Liu Z et al. Exp Cell Res, June 2021 (epub ahead of print)
May 2021
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib. ENESTop 5-year update Hughes TP et al. Leukemia, May 2021 (epub ahead of print)	Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemic Lee H et al. Int J Hematol, May 2021
Why chronic myeloid leukemia cannot be cured by tyrosine kinase inhibitors Baccarani M and Gale RP. Leukemia, May 2021 (epub ahead of print)	Suppression of USP1 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis Jiang S et al. Cell Death Dis, May 2021 – open access publication
EUTOS long-term survival score discriminated different SOKAL score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study Breccia M et al. Leukemia, May 2021 (epub ahead of print)	Mutational landscape of chronic myeloid leukemia: more than a single oncogene Adnan-Awad S et al. Leuk Lymphoma, May 2021 (epub ahead of print)
Budget impact of tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia with sustained deep molecular response Astruge C et al. Value Health, May 2021	Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review Torres-Barrera P et al. Curr Res Transl Med, May 2021 (epub ahead of print)
Relevance of treatment-free remission recommendations in chronic phase chronic myeloid leukemia patients treated with frontline tyrosine kinase inhibitors Etienne G et al. Cancer Med, May 2021 (epub ahead of print) – open access publication	Validation of CIP2A as a biomarker of subsequent disease progression and treatment failure in chronic myeloid leukemia Clark RE et al. Cancers(Basel), May 2021 – open access publication
Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients Folta A et al. Leuk Lymphoma, May 2021	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation in chronic myeloid leukemia Ochi Y et al. Nat Commun, May 2021 – open access publication
Promyelocytic blast phase of chronic myeloid leukemia; BCR-ABL1 positive: Points to be considered at diagnosis Kim B et al. Ann Lab Med, May 2021 – open access publication	Sirtuin1 and chronic myeloid leukemia: A comprehensive glance of drug resistance Abbasian S et al. Clin Lab, May 2021
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: A real-world analysis of health plan enrolees Chow EJ et al. Leuk Lymphoma, May 2021
An indirect comparison between bosutinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia Muresan B et al. Curr Med Res Opin, May 2021 (epub ahead of print)
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib Hall KH et al. Am J Hematol, May 2021 (epub ahead of print) – open access publication
Current status and novel strategy for CML Morita K and Sasaki K. Int J Hematol, May 2021
April 2021
Asciminib in chronic myeloid leukemia: Many questions still remain to be answered Eskazan AE. Blood Cancer J, April 2021 – open access publication	Recent advances in understanding chronic myeloid leukemia: Where do we stand? Kumar R and Krause DS. Fac Rev, April 2021 – open access publication
Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib Morita K et al. Cancer, April 2021 (epub ahead of print)	Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape Hsieh YC et al. Leukemia, April 2021 (epub ahead of print) – open access publication
Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population based study Jamy O et al. Am J Hematol, April 2021 (epub ahead of print) - open access publication	Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy Schoepf AM et al. Eur J Med Chem, April 2021 – open access publication
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial Kim DDH et al. Br J Haematol, April 2021 (epub ahead of print)	An aging mouse model of human chronic myeloid leukemia Hao T et al. Oncogene, April 2021 (epub ahead of print)
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial Chuah C et al. Int J Hematol, April 2021 (epub ahead of print)	Repositioning antispasmodic drug papaverine for the treatment of chronic myeloid leukemia Parcha PK et al. Pharmacol Rep, April 2021
Bosutinib-related pleural effusion in patients with chronic myeloid leukemia Yüzbasloglu MB and Eskazan AE. Expert Opin Drug Saf, April 2021	The regulation of bcr-abl in hypoxia is through the mTOR pathway Clapper E et al. Leuk Lymphoma, April 2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up Scalzulli E et al. Leuk Lymphoma, April 2021	Leukemic stem cells shall be searched in the bone marrow before tyrosine kinase inhibitor-discontinuation in chronic myeloid leukemia Ilhan O et al. Int J Lab Hematol, April 2021 (epub ahead of print)
When to stop TKIs in patients with chronic myeloid leukemia and how to follow them subsequently Cerveira N et al. Curr Treat Options Oncol, April 2021	Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase Alswied A et al. Cancer Genet, April 2021
Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review Heiney SP et al. Am J Clin Oncol, April 2021 (epub ahead of print)
March 2021
Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase Castagnetti F et al. Front Oncol, March 2021 – open access publication	Targeting chronic myeloid leukemia stem/progenitor cells using Venetoclax-loaded immunoliposome Houshmand M et al Cancers(Basel), March 2021 – open access publication
Third-line therapy for chronic myeloid leukemia: Current status and future directions Cortes J and Lang F. J Hematol Oncol, March 2021 – open access publication	Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study Ottmann OG et al. Leuk Lymphoma, March 2021
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial Radich JP et al. Leukemia, March 2021 (epub ahead of print) – open access publication	Treatment-free remission and immunity in chronic myeloid leukemia Ureshino H. Int J Hematol, March 2021 (epub ahead of print)
Asessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network Schäfer V et al. J Cancer Res Clin Oncol, March 2021 (epub ahead of print) – open access publication	New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism Naka K. Int J Hematol, March 2021 (epub ahead of print)
Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates Atallah EL et al. Leuk Lymphoma, March 2021 (epub ahead of print)	Efficiency of nilotinib to target chronic-phase chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells Berger MG et al. Sci Rep, March 2021 – open access publication
The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study Martínez-López J et al. Leuk Lymphoma, March 2021 (epub ahead of print)	The discovery of novel BCR-ABL tyrosine kinase inhibitors using a pharmacophore modelling and virtual screening approach Huang TT et al. Front Cell Dev Biol, March 2021 – open access publication
I rock the boat? When to stop TKI’s in CML? Nazha A. Blood, March 2021	Discovery of a novel CIP2A variant (NOCIVA) with clinical relevance in predicting TKI resistance in myeloid leukemias Makela E et al. Clin Cancer Res, March 2021 (epub ahead of print) – open access publication
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience Pepe S et al. Leuk Lymphoma, March 2021 (epub ahead of print)	Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogeneic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B Bencome-Alvarez AE, Oncogene, March 2021 (epub ahead of print) – open access publication
Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world setting in France: The POST-PACE study Etienne G et al. Leuk Res, March 2021 (epub ahead of print)	Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of CML progression Sloma I et al. Haematologica, March 2021 – open access publication
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients Scalzulli E et al. Ann Hematol, March 2021 (epub ahead of print)
arly BCR-ABL kinetics are predictive of subsequent achievement of treatment-free-remission in CML Shanmunagathan N et al. Blood, March 2021
February 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKI’s: First interim analysis of OPTkIMA study Malagola M et al. Cancer Med, February 2021 (epub ahead of print) - open access publication	Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression Clark RE et al. Blood Adv, February 2021 - open access publication
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR – final report from AFTER-SKI Richter J et al. Leukemia, February 2021 (epub ahead of print) – open access publication	Eradicating residual chronic myeloid leukemia: basic research lost in translation Zhao H and Deininger M. Lancet Haematol, February 2021
Mortality rates in patients with chronic myeloid leukemia in chronic phase with frontline second generation kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) Breccia M et al. Ann Hematol, February 2021	Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFTM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib Hrdinova T et al. Int J Oncol, February 2021
Dose-optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: A new therapeutic challenge Iurlo A et al. J Clin Med, February 2021 – open access publication	Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells Ozkan T et al. Leuk Res, February 2021 (epub ahead of print)
Bosutinib in the real-life treatment of chronic myeloid leukemia patients >65 years resistant/intolerant to previous tyrosine-kinase inhibitors Latagliata R et al. Hematol Oncol, February 2021 (epub ahead of print)	Circulating miR-1461 expression to imatinib in adult chronic myeloid leukemia Habib EM et al. J Investig Med, February 2021
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice Garcia-Gutiérrez V et al. Blood Cancer J, February 2021 – open access publication	Future approaches for treating chronic myeloid leukemia: CRISP therapy Vuelta E et al. Biology(Basel), February 2021 – open access publication
MR4 log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial Seguro FS et al. Leuk Res, February 2021	Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells Yahata T et al. Haematologica, February 2021 – open access publication
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors Efficace F et al. Expert Rev Hematol, February 2021 (epub ahead of print)	Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation? Frikha R et al. J Oncol Pharm Pract, February 2021 (epub ahead of print)
ong-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy Cortes JE et al. Eur J Haematol, February 2021 (epub ahead of print)	The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: A systematic review and meta-analysis Ghalesardi OK et al. Leuk Res, February 2021
	Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) Lu T et al. Eur J Pharmacol, February 2021 (epub ahead of print)
January 2021
Clinical outcomes of patients with chronic myeloid leukemia with concurrent core binding factor rearrangement and Philadelphia chromosome Morita K et al. Clin Lymphoma Myeloma Leuk, January 2021 (epub ahead of print)	The giant HECT E3 ubiquitin ligase HERC1 is aberrantly expressed in myeloid related disorders and it is a novel BCR-ABL1 binding partner Ali MS et al. Cancers(Basel), January 2021 – open access publication
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed CML in chronic phase: ENESTnd 10-year analysis Kantarjian HM et al. Leukemia, January 2021 (epub ahead of print) – open access publication	Genetic screening for potential new targets in chronic myeloid leukemia based on Drosophia Transgenic for human BCR-ABL Lo Iacono M et al. Cancers(Basel), January 2021 – open access publication
I Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukemia: results from the French SPIRIT phase III randomised trial Guilhot F et al. Leukemia, January 2021 (epub ehead of print)	The quiescent fraction of chronic myeloid leukemia stem cells depends on BMPR1B, STAT3, and BMP4-niche signals to persistent in patients in remission Jeanpierre S et al. Haematologica, January 2021 – open access publication
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice? Colafigli G et al. Crit Rev Oncol Hematol, January 2021	HLA polymorphis are associated with treatment-free re mission following discontinuation of TKI’s in CML Ureshino H et al. Mol Cancer Ther, January 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia in patients treated with nilotinib Caocci G et al. Ann Hematol, January 2021 (epub ahead of print)	Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTor pathway in combination with TKIs: A review Singh P et al. Med Oncol, January 2021
Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data Gambarcoti-Passerini C et al. Eur J Haematol, January 2021 – open access publication	The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration Ito F et al. Int J Hematol, January 2021
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real-life Santoleri F et al. Curr Med Res Opin, January 2021 (epub ahead of print)	NT157, an IGF1R-IRS1/2 inhibitor exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia Scopim-Ribeiro R et al. Invest New Drugs, January 2021 (epub ahead of print)
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukemia in the United Kingdom: the UK TARGET CML study Milojkociv D et al. Br J Haematol, January 2021 – open access publication
BCR-ABL kinase domain mutation analysis by Next Generation Sequencing detected additional mutations in CML patients with suboptimal response to Nilotinib Benjamin ESB et al. Leuk Lymphoma, January 2021 (epub ehead of print)

Publications on COVID-19 and CML/Cancer - 2021

December 2021

Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic leukemia patients on tyrosine kinase inhibitors
Claudiani S et al. Br J Haematol, December 2021 (epub ahead of print) – open access publication
Safety of SARS-CoV-2 vaccines in patients with chronic myeloid leukemia: a multicentre survey in China
Yang et al. Clin Med J (Engl), December 2021 (epub ahead of print) – open access publication
Outcome of COVID-19 in patients with CML: A single centre UK experience
Nesr G et al. J Med Virol, December 2021 (epub ahead of print)
Serum antibody response in patients with Philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines
Kozak KE et al. Leukemia, December 2021 – open access publication
Evaluation of COVID-10 vaccine response in patients with cancer: An interim analysis
Tran S et al. Eur J Cancer, December 2021 – open access publication
Immune response following third COVID-19 vaccination are reduced in patients with haematological malignancies compared to patients with solid cancer
Fendler A et al. Cancer Cell, December 2021 (epub ahead of print) – open access publication
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with haematological malignancies
Tamariz-Amador LE. Blood Cancer J, December 2021 – open access publication
Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with haematological malignancies
Re D et al. Leuk Lymphoma, December 2021
Systematic screening for SARS-CoV-2 in patients with haematological malignancies on active anticancer treatment in the outpatient setting
Varettoni M et al. Leuk Lymphoma, December 2021
Efficacy and safety of heterologous booster vaccination with Ad26Cov2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response
Reimann P et al. Br J Haematol, December 2021 (epub ahead of print) – open access publication
Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis
Gagelmann N et al. Haematologica, December 2021 (epub ahead of print) – open access publication

November 2021

Is COVID-19 less severe in CML patients than in those with other haematological cancers?
Claudiani S. Br J Haematol, October 2021 (epub ahead of print) – open access publication
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients
Benda M et al. B J Haematol, November 2021 – open access publication
COVID-19 in vaccinated adult patients with haematological malignancies: preliminary results from EPICOVIDEHA
Pagano L et al. Blood, November 2021 (epub ahead of print)

October 2021

COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A campus CML report
Breccia M et al. Br J Haematol, October 2021 (epub ahead of print) - open access publication
COVID-19 infection in adult patient with haematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Pagano L et al. J Hematol Oncol, October 2021 – open access publication
Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials. Lessons from the CounterCOVID-imatinib study
Bartelink IH et al. CPT Pharmacometics Syst Pharmacol, October 2021
(epub ahead of print) – open access publication
COVID-19 and seasonal influenza: a comparative analysis in patients with haematological malignancies
Modemann F et al. Leuk Lymphoma, October 2021 (epub ahead of print)
BNT162b2 COVID-19 vaccine is significantly less effective in patients with haematological malignancies
Herzog-Tzarfati K et al. Am J Hematol, October 2021 – open access publication
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish National study
Weclawek-Tampol J et al. J Hematol Oncol, October 2021 – open access publication

September 2021

The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population
Bonifacio M et al. Cancer Med, September 2021 – open access publication
Clinical profile and outcomes of COVID-19 in haematological malignancies: experience from tertiary care centre in India
Gupta A et al. Ann Hematol, September 2021 (epub ahead of print)
Clinical characteristics and outcomes of patients with haematological malignancies and COVI-19 suggest that prolonged SARS-CoV-2 carriage is an important issue
Arcani R et al. Ann Hematol, September 2021 (epub ahead of print) – open access publication
Implementation of a hospital-at-home (HAH) unit for haematological patients during the COVID-19 pandemic: safety and feasibility
Gómez-Centurión I et al. Int J Hematol, September 2021 (epub ahead of print) – open access publication

August 2021

The care of the leukemic patients in times of SARS-CoV-2
Karki NK et al. Curr Oncol Rep, August 2021 – open access publication
A novel system for semiautomatic sample processing in chronic myeloid leukemia: Increasing throughput without impacting on molecular monitoring at time of SARS-CoV-2 pandemic
Stella S et al. Diagnostics (Basel), August 2021 – open access publication
COVID-19 among patients with haematological malignancies: A national Israeli retrospective analysis with special emphasis on treatment and outcome
Levy I et al. Leuk Lymphoma, August 2021 (epub ahead of print)
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
Malard F et al. Blood Cancer J, August 2021 – open access publication
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Greenberger LM et al. Cancer Cell, August 2021 – open access publication
Multiple cranial nerve palsies revealing blast crisis in patient with chronic myeloid leukemia in the accelerated phase under nilotinib during severe infection with SARS-CoV-19 virus: Case report and review of literature
Bouchlarhem A et al. Radiol Case Rep, August 2021 (epub ahead of print) – open access publication
Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study
Mukkada S et al. Lancet Oncol, August 2021 (epub ahead of print)
Seroconversion and kinetic of anti SARS-CoV-2 antibodies in 25 patients with haematological malignancies who recovered from SARS-CoV-2 infection
Candoni A et al. Hematol Oncol, August 2021 – open access publication

July 2021

COVID-19 in chronic myeloid leukemia patients in Latin America
Pagnano KB et al. Leuk Lymphoma, July 2021 (epub ahead of print)
Preclinical evaluation of imatinib does not support its use as an antiviral drug against SARS-CoV-2
Touret F et al. Antiviral Res, July 2021 (epub ahead of print) – open access publication
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
Passamonti F et al. Br J Haematol, July 2021 (epub ahead of print) – open access publication

June 2021

Single dose BNT162b1 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with CML
Harrington P et al. Br J Haematol, June 2021 (epub ahead of print)
– open access publication
Mental health in persons with chronic myeloid leukemia during the SARS-CoV-2 pandemic: The need for increased access to healthcare services
Bao M et al. Front Psychiatry, June 2021 – open access publication
The impact of COVID-19 on patients with haematological malignancies: the mixed-method analysis of an Israeli National survey
Levy I et al. Support Care Cancer, June 2021 (epub ahead of print) – open access publication
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicentre prospective survey
Ljungman P et al. Leukemia, June 2021 (epub ahead of print) – open access publication
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and cancer Consortium
Grivas P et al. Ann Oncol, June 2021 – open access publication
Epidemiological and clinical characteristics of cancer patients with COVID-19: A systematic review and meta-analysis of global data
Kong X et al. Cancer Lett, June 2021 – open access publication

May 2021

Impact of COVID-19 on cancer care in India: A cohort study
Ranganathan P et al. Lancet Oncol, May 2021 (epub ahead of print) - open access publication
When hematologic malignancies meet COVID-19 in the United State: Infections, death and disparities
Wang Q et al. Blood Rev, May 2021
COVID-19 among children with cancer in Greece (2020). Results from the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumours (NARECHEM-ST)
Baka M et al. Pediatr Blood Cancer, May 2021 (epub ahead of print) - open access publication
COVID-19 vaccines for patients with haematological conditions
Sun C et al. Lancet Hematol, May 2021 – open access publication
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies
Desai A et al. Cancer, May 2021 – open access publication
Comparison and impact of COVID-19 for patients with cancer: a survival analysis of fatality rate for age, sex and cancer type
Li H et al. BMJ Health Care Inform, May 2021 – open access publication

April 2021

Clinical characteristics and risk factors for mortality in cancer patients with COVID-19
Liang J et al. Front Med, April 2021 – open access publication
2021 update of the AGIHO Guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnosis, viral shredding, vaccination and therapy
Giesen N et al. Eur J Cancer, April 2021 – open access publication
Consequences of the COVID-19 pandemic on cancer clinical trials
Flores S et al. Cancer Med J, April 2021 – open access publication
Impact of cancer history on outcomes among hospitalized COVID-19 patients
Klein IA et al. Oncologist, April 2021 – open access publication
COVID-19 and cancer – 1 year on
The Lancet Oncology, April 2021 – open access publication

March 2021

Early administration of convalescent plasma improves survival in patients with haematological malignancies and COVID-19
Biernat MM et al. Viruses, March 2021 – open access publication
Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic
Osterman CK et al. Support Care Cancer, March 2021 – open access publication
COVID-19 in chronic-phase chronic myeloid leukemia patients: A single-center survey from Turkey
Yilmaz U et al. Turk J Haematol, February 2021 – open access publication
Blurring of vision as the only symptom of undiagnosed case of chronic myeloid leukemia in the COVID-19 era
Gumaste P and Vairagyam R. Indian J Ophthalmol, March 2021 – open access publication
Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKI’s) without interruption
Demeter J et al. Mediterr J Hematol Infect Dis, March 2021 – open access publication
COVID-19 in patients with haematological malignancies: Considering the role of tyrosine kinase inhibitors
Morale-Ortega A et al. Cancer, March 2021 (epub ahead of print) – open access publication
Reply to COVID-19 in patients with haematological malignancies: Considering the role of tyrosine kinase inhibitors
Cattaneo C et al. Cancer, March 2021 (epub ahead of print) – open access publication
Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review
Prasad Meena J et al. Pediatr Blood Cancer, March 2021 (epub ahead of print) – open access publication
Challenges and opportunities for COVID-19 vaccines in patients with cancer
Kuderer NM et al. Cancer Invest, March 2021

February 2021

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
Jacobs CF et al. Blood Adv, February 2021 - open access publication
ASH registry offers insights on COVID-19 in patients with haematological malignancies
Oncologist, February 2021 – open access publication
Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time
Cattaneo C et al. Leukemia, February 2021 – open access publication
Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited
Ribas A et al. Cancer Discov, February 2021
Cancer patients and COVID-19: Mortality, serious complications, biomarkers, and ways forward
Gupta K et al. Cancer Treat Res Commun 2021 - open access publication

January 2021

COVID-19 induced Pancytopenia in a major molecular response CML patient on dasatinib: A case report and review of the literature
Singh B et al. Eur J Case Rep Intern Med, January 2021 – open access publication
Lymphopenia as a biological predictor of outcomes in COVID-19 patients: A Nationwide Cohort Study
Lee J et al. Cancers(Basel), January 2021 – open access publication

Page 1 of 6

Copyright © 2023 All Rights Reserved. The iCMLf is registred as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK